Neuphoria's Phase 3 AFFIRM-1 failure ended its lead programme, R&D spending fell 60.6% and a $5.4M goodwill writedown followed Merck's termination of the MK-1167 Alzheimer's trial — leaving a one-employee company with $19.9M of cash being sold to Scancell at a $24.6M valuation.
A failed Phase 3 ended the science; what's left is a cash balance and a sale
Neuphoria Therapeutics (Nasdaq: NEUP) spent fiscal 2026 — the year ended June 30, 2026 — dismantling itself. On October 20, 2025 the company announced that AFFIRM-1, its Phase 3 trial of lead drug candidate BNC210 for the acute treatment of social anxiety disorder, "did not meet its primary endpoint, and secondary endpoint analysis did not show statistically significant differences or improvement over placebo." A Phase 3 trial is the final, largest human study a drug normally needs before regulators will consider approving it; the primary endpoint is the single pre-declared measure the trial is judged on. AFFIRM-1 enrolled roughly 332 adults and tested a single 225 mg dose against placebo during a public-speaking challenge. It failed. The company discontinued the social-anxiety program, never started the planned follow-on AFFIRM-2 trial, and paused SYMPHONY, the Phase 2b/3 trial it had designed for post-traumatic stress disorder.
Within days management committed to a restructuring: it terminated its facility leases, terminated substantially all employees, and — per Item 1 of the 10-K — "retained only one full-time employee," running the company through consultants, including an interim CEO engaged on that basis. Nine months later, on July 23, 2026, Neuphoria signed an agreement to be acquired by Scancell Holdings plc, a UK-listed biotech.
So the fiscal 2026 accounts are not the accounts of a drug developer. They are the accounts of a company preserving a cash balance while it negotiates its own sale.
Read 0 community reports on Neuphoria Therapeutics Inc., or write your own.Write a report
$3.55M
$9.01M
−60.6%
General and administrative expense
$7.44M
$7.77M
−4.3%
Total operating expenses
$17.63M
$16.78M
+5.0%
Loss from operations
$(16.45)M
$(1.13)M
loss 14.6x larger
Net loss
$(13.45)M
$(0.37)M
loss 36.4x larger
Loss per share, basic and diluted
$(3.06)
$(0.23)
loss per share 13.3x larger
Cash and cash equivalents at year end
$19.87M
$14.21M
+39.8%
Net cash used in operating activities
$(12.35)M
+$0.08M
swung to $12.4M outflow
Cash runway at FY2026 burn rate
~19 months
not meaningful
—
Shares outstanding at year end
5,411,334
1,978,460
+173.5%
Accumulated deficit
$191.80M
$178.35M
+$13.45M
Cash runway is the number of months a company can keep operating before its cash is gone. Here it is $19.87M of cash divided by fiscal 2026's operating cash burn of $12.35M, or about $1.03M a month. FY2025 is marked "not meaningful" because operations actually generated a small amount of cash that year — there was no burn to divide into.
The 92.5% revenue collapse is a comparison artifact, not a deterioration
Neuphoria has never sold a product. What it books as revenue is money from partners. FY2025's $15.65M of license revenue was almost entirely a single event: a $15.0M milestone payment received on March 19, 2025 when Merck first dosed a patient in a Phase 2 trial of MK-1167, a compound licensed from Neuphoria. (The remainder ties to an A$1.0M milestone from Carina Biotech received October 30, 2024.) A milestone payment is a one-time fee triggered by a partner hitting a defined step — it does not repeat.
FY2026's $1.17M is a different line entirely: collaborative arrangement revenue from the Australian Cancer Therapeutics CRC, in which Neuphoria holds an approximate 4.65% participation interest. License revenue in FY2026 was zero. The MD&A states the decline was "primarily due to the non-recurring $15.0 million licensing milestone payment received from the Merck Agreement" in the prior year. Read the two years as $1.17M of recurring partner income against a prior year inflated by one cheque.
Spending fell much harder than the expense total suggests
Total operating expenses actually rose 5.0%, to $17.63M. That masks the real cut. Cash operating spending — R&D plus G&A — fell from $16.78M to $10.98M, a decline of $5.79M or 34.5%. The increase in the headline total comes entirely from two items that did not exist in FY2025: $1.28M of restructuring costs and a $5.36M non-cash goodwill impairment.
R&D dropped 60.6% because there was almost nothing left to fund. The MD&A is blunt: there were "no research and development activities being run directly by the Company for any non-BNC210 related product candidates" in the December, March and June quarters, and with the PTSD pause still in effect the company "expects its directly funded research and development activity and expense to remain limited."
G&A barely moved, down $0.33M. Management attributes that to "decreases in headcount-related costs of $1.0 million resulting from the previously announced entity restructuring in October 2025, partially offset by increases in administrative costs of $0.7 million directly related to supporting the upcoming potential strategic event." In plain terms: firing nearly everyone saved $1.0M, and the bankers, lawyers and proxy work for the sale process ate $0.7M of it back. At $7.44M, G&A is more than six times R&D — the spending profile of a deal, not a drug.
The $5.4M goodwill writedown is the second scientific failure of the year
Goodwill is an accounting leftover from past acquisitions: the amount paid above the measurable value of what was bought. It sits on the balance sheet until the business no longer supports it, at which point it must be written down.
On July 1, 2026 — after the fiscal year closed but before the books were finalised — Merck announced it had cancelled the Phase 2 Alzheimer's trial of MK-1167, "after an interim analysis indicated the drug did not meet the efficacy criteria required to justify continuing." This is the same compound whose trial start had produced Neuphoria's $15.0M milestone sixteen months earlier. Management treated the cancellation as an impairment indicator, hired an independent valuation firm, and recorded a $5,362,000 charge at June 30, 2026, "primarily due to downward revisions of the expected future cashflows associated with the potential commercialization of Merck's MK-1167." Goodwill fell from $8.86M gross to $3.50M.
The charge is non-cash — it does not touch the bank balance — but it is economically real. Neuphoria remains eligible for up to $450M in further Merck milestones plus tiered royalties running from low-single-digit to low-sub-teens percentages of net sales, and MK-4334 has completed Phase 1. But the most advanced asset in that collaboration is now dead, and the company's own auditor-supported valuation says so.
Cash went up — because shareholders were diluted, not because the business improved
Cash and equivalents rose $5.65M to $19.87M. The cash-flow statement shows how: operations consumed $12.35M while financing supplied $17.92M. Essentially all of the financing was the at-the-market equity programme, under which Neuphoria "issued an aggregate of 3,398,869 shares of common stock… receiving gross proceeds in the aggregate amount of approximately $18.5 million" during FY2026. An at-the-market, or ATM, facility lets a company sell new shares into the open market a little at a time at prevailing prices.
The cost was severe. Shares outstanding went from 1,978,460 to 5,411,334 — up 173.5%. Weighted-average shares used for loss per share rose from 1.62 million to 4.40 million. That is why loss per share worsened only 13.3x while the net loss worsened 36.4x: the loss was spread across nearly three times as many shares.
Those shares were sold at an average of roughly $5.44 each ($18.5M over 3,398,869 shares). The merger agreement signed six weeks after year-end values the entire company at $24,598,949 — about $4.55 per share across the 5,411,334 shares outstanding, and less than that on the fully diluted basis the exchange-ratio formula actually uses. Investors who bought on the ATM through the year, on average, paid more per share than the agreed sale values their stock at. For context, Lynx1 Master Fund had made a non-binding all-cash proposal of $5.20 per share on November 10, 2025, withdrew it on November 18, and revised it to $4.75 per share on December 2, 2025.
Management states that, "reflective of recent cost curtailments," existing cash will fund operations "beyond the second quarter of fiscal year 2028" — that is, beyond December 2027 — and concluded there is no substantial doubt about the company's ability to continue as a going concern. The balance sheet supports that: $19.87M of cash against total liabilities of just $4.11M, of which only $0.76M is current. There is no debt.
What shareholders actually get from the Scancell merger
Each Neuphoria share converts into a number of Scancell American Depositary Shares plus one contingent value right. On the assumptions disclosed — a Scancell Valuation of $144,612,002, a Neuphoria Valuation of $24,598,949, and $38.6M of gross PIPE (private placement) proceeds — pre-merger Neuphoria stockholders are expected to hold approximately 11.1% of the combined company, existing Scancell shareholders approximately 64.9%, and PIPE subscribers approximately 17.3%, with roughly 7.0% from a planned ~$12.0M UK institutional placing and a retail offer of up to $3.0M.
The contingent value right is where Neuphoria's remaining science ends up. Each CVR entitles the holder to a pro rata share of 100% of net proceeds Scancell actually receives from: the Merck collaboration for 15 years after completion; the CRC participants' arrangements including the existing Pfizer KAT6 licence, also for 15 years; certain permitted monetisations of Neuphoria intellectual property; and Neuphoria's Australian R&D tax credit for the year ended June 30, 2026. The CVRs are non-transferable, unlisted, carry no voting or dividend rights, and — the filing says plainly — "there can be no assurance that any CVR holder will receive a payment."
That structure makes sense of a pointed disclosure in Item 1: Scancell "does not intend to develop Neuphoria's non-partnered assets after closing" beyond de minimis costs to maintain and enforce the agreements and IP. BNC210 in PTSD is a non-partnered asset. The buyer is not buying the drug. It is buying a Nasdaq listing, roughly $20M of cash, and partner royalty streams it will pass through to CVR holders anyway.
What to watch
Closing is targeted for late calendar 2026, with an outside date of February 28, 2027 (extendable 60 days if the SEC has not declared the Form F-4 registration statement effective). Three conditions matter more than the rest:
Scancell must raise at least $75.0M in gross cash proceeds from the concurrent financing, at or just before closing. This is the largest execution risk and sits entirely with the buyer, not with Neuphoria.
Neuphoria must show at least $10.0M of closing net cash as of December 31, 2026 or at closing, whichever is earlier. At $19.87M on June 30 and roughly $1.0M a month of burn — and with active R&D shut off, the true run-rate is likely lower — this condition has meaningful headroom, but it is also why any drawn-out delay past mid-2027 starts to bite.
Both shareholder votes. Directors, officers and certain significant holders have signed voting and support agreements, but the board remains obliged to hold the vote even if it changes its recommendation in favour of a superior offer, and it cannot terminate the agreement to accept one.
There is no management guidance in any conventional sense — no revenue forecast, no trial timeline, no spending plan. The company says only that R&D expense would "increase substantially" if development ever resumed, under Scancell or under a Neuphoria that stays independent.
My read: the downside here is bounded and the upside is thin. With $19.87M of cash, $4.11M of total liabilities, one employee and essentially no operating commitments, the balance sheet is close to a liquid shell — which is precisely what makes the deal financeable. But the equity is being exchanged at a valuation below the ATM prices shareholders paid through the year and below both of Lynx1's cash indications, and the science that would justify a higher number has been failing rather than compounding: AFFIRM-1 missed in October, Merck's MK-1167 was terminated for futility in June, and the PTSD programme that actually produced a positive Phase 2b result (ATTUNE, 212 patients, primary endpoint met at Week 12, p=0.048) sits paused with a buyer who has said it does not plan to develop it. Practically, holders are trading a cash-backed shell for 11.1% of a different company's pipeline plus a lottery ticket on Merck and Pfizer royalties. The CVR is the only line in the deal that could pay off large, and it pays only if partners Neuphoria does not control succeed with programmes it no longer funds.
Takeaway: Neuphoria's headline metrics are noise — the 92.5% revenue drop is the absence of last year's one-off $15M Merck milestone, and the 36x worse net loss is mostly a $5.4M non-cash goodwill writedown plus $1.3M of restructuring. The number that matters is $19.87M of cash against $4.11M of total liabilities and one remaining employee, being handed to Scancell at a $24.6M valuation — roughly $4.55 a share, below the ~$5.44 average price at which the company sold 3.4 million new shares into the market during the same year.
Source: Neuphoria Therapeutics Inc. Form 10-K for the fiscal year ended June 30, 2026, filed with the SEC on September 18, 2026 (accession no. 0001193125-26-395536). All figures are as reported in the audited consolidated financial statements and Item 7 MD&A; percentage and per-month calculations are derived from those reported figures.